ReNeuron’s interim results highlight the positive progress of its stem cell therapy candidates. Positive long term data from a Phase II trial (PISCES II) evaluating CTX stem cell therapy candidate for stroke was announced in October and an IND has been approved (announced this morning) to commence a Phase IIb (PISCES III) trial. It is still expected to start in H1 2018 with data in late 2019. The Phase I element of the ongoing Phase I/II trial evaluating the group’s hRPC stem cell therapy in retinitis pigmentosa was successfully completed with the Phase II portion on going. Initial Phase II data continues to be anticipated in H2 2018. We remain upbeat and look forward to the upcoming newsflow from ReNeuron’s pipeline.
